Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS1-144 in Moderate to Severe Vasomotor Symptoms in Chinese Postmenopausal Women
NCT06726850Phase 2Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in vasomotor symptoms comparing Placebo with GS1-144 tablet (2 arms). Primary endpoint: Changes from baseline in the frequency of moderate to severe VMS at 12 weeks. Started Oct 2024; status: completed.
02
Drugs
GS1-144
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT06726850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06726850.